Experienced in Melanoma

Chris Wratten

Edith St, 
Waratah, NSW, AU 
Experienced in Melanoma
Edith St, 
Waratah, NSW, AU 
OverviewLocationsClinical Research

Overview

Chris Wratten practices in Waratah, Australia. Mr. Wratten is rated as an Experienced expert by MediFind in the treatment of Melanoma. His top areas of expertise are Malnutrition, Milroy Disease, Lymphedema, Neuroendocrine Tumor, and Gastrostomy.

His clinical research consists of co-authoring 41 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles and participated in 3 clinical trials in the study of Melanoma.

Gender
Male

Locations

Edith St, Waratah, NSW 2298, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomised Trial of Post-operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck
A Randomised Trial of Post-operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck
Enrollment Status: Completed
Publish Date: November 27, 2024
Intervention Type: Other, Radiation
Study Phase: Not Applicable
A Randomised Controlled Multicentre Trial of Imiquimod Versus Radiotherapy for Lentigo Maligna (LM) When Staged Surgical Excision With 5mm Margins is Not Possible, is Refused, or Fails
A Randomised Controlled Multicentre Trial of Imiquimod Versus Radiotherapy for Lentigo Maligna (LM) When Staged Surgical Excision With 5mm Margins is Not Possible, is Refused, or Fails
Enrollment Status: Completed
Publish Date: June 20, 2024
Intervention Type: Drug, Radiation
Study Drug: Imiquimod
Study Phase: Phase 3
TROG12.01 A Randomised Trial of Weekly Cetuximab and Radiation Versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma
TROG12.01 A Randomised Trial of Weekly Cetuximab and Radiation Versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma
Enrollment Status: Unknown
Publish Date: November 18, 2022
Intervention Type: Drug, Radiation
Study Drugs: Cetuximab, Cisplatin
Study Phase: Phase 3
Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma - A Randomised Phase III Trial
Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma - A Randomised Phase III Trial
Enrollment Status: Unknown
Publish Date: January 07, 2021
Intervention Type: Radiation
Study Phase: Not Applicable
View 3 Less Clinical Trials

41 Total Publications

Prognostic Subgroups for Disease-Free Survival With Cutaneous Squamous Cell Carcinoma of the Head and Neck: A Secondary Analysis of a Randomized Clinical Trial.
Prognostic Subgroups for Disease-Free Survival With Cutaneous Squamous Cell Carcinoma of the Head and Neck: A Secondary Analysis of a Randomized Clinical Trial.
Journal: JAMA otolaryngology-- head & neck surgery
Published: August 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Wratten's expertise for a condition
ConditionClose
        View All 10 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile